INDY Reduction Affects Metabolism, Health, and Longevity
========================================================

The *Indy* (*I'm Not Dead Yet*) gene encodes the fly homolog of the mammalian SLC13A5 transporter of the tricarboxylic acid (TCA) cycle intermediates ([@B31]; [@B20], [@B19]). INDY is a member of the SLC13 protein family of Na^+^-coupled di- and tri-carboxylate/sulfate transporters in prokaryotes and eukaryotes ([@B1]). In flies, INDY mediates a cation independent and electroneutral high affinity bidirectional transport of the TCA intermediate across the plasma membrane ([@B20], [@B19]). Fly INDY has the highest substrate affinity for transporting citrate and lower affinities to other Krebs cycle intermediates such as succinate, malate, and fumarate ([@B20], [@B19]). INDY homologs in bacteria and mammals have the highest affinity for transporting citrate, and lower for other Krebs cycle intermediates but this transport is Na-dependent. The Na-citrate stoichiometry is 1:1 in bacteria and 4:1 for mINDY ([@B14],[@B15]; [@B1]; [@B35]).

Although all mammalian INDY transporters are Na^+^-dependent, the human mINDY is a high-capacity and low affinity transporter, while the rodent mINDY are low-capacity and high affinity transporters ([@B1]; [@B35]).

Reduced expression of the *Indy* gene in flies and worms extends longevity in all but one study ([@B31]; [@B7], [@B8]; [@B34]; [@B36]; [@B30]; [@B28]; [@B32]). INDY is expressed on the plasma membrane of metabolically active tissues. In flies INDY is predominantly expressed in the midgut, fat body, and oenocytes (fly liver) ([@B31]; [@B20]). In humans, *Indy* mRNA is mainly expressed in the liver, less in the brain and testis, while small levels of *Indy* mRNA expression were found in the kidneys, thymus, ovaries, adipose tissue, stomach, and colon ([@B15]; [@B35]). Decreased expression of *Indy* in worms, flies, mice, and rats alters metabolism in a manner similar to calorie restriction (CR; [@B31]; [@B7]; [@B5]; [@B23]; [@B36]; [@B2]; [@B32]). This is supported by similar phenotypes found in CR wild type flies and in *Indy* flies that were kept on a high calorie diet. These *Indy* flies have lower lipid levels, increased mitochondrial biogenesis, increased spontaneous physical activity and a reduction in components of the insulin-signaling pathway activity (**Figure [1](#F1){ref-type="fig"}**; [@B23]; [@B36]; [@B28]). *Indy* flies are protected from weight gain when aged on a high calorie diet ([@B36]). Under standard condition, heterozygous *Indy* flies do not experience any negative effects on health and have the same negative geotaxis, metabolic rate and maximal flight velocity ([@B22]). Furthermore, *Indy* heterozygous flies laid more eggs during their life compared to controls ([@B22]). However, under CR condition, *Indy* heterozygous flies have reduced fecundity due to lower energy resource caused by the effect of reduced *Indy* on metabolism ([@B22]). Consistently, CR does not further extend longevity of long-lived *Indy* heterozygous flies and shortens longevity of *Indy* homozygous flies ([@B36]).

![**Genetics and pharmacological manipulations that result in hepatic *Indy* reduction prevent negative effects of a high fat diet and promote health and longevity**. INDY reduction increases mitochondrial biogenesis, insulin sensitivity, β-oxidation, and preserves intestinal stem cell homeostasis. Reduced INDY decreases *de novo* lipogenesis and hepatic lipid accumulation. Decrease in INDY transporting activity prevents fatty liver disease, insulin resistance, and weight gain.](fgene-08-00066-g001){#F1}

Preservation of intestinal stem cell (ISC) homeostasis has a key role in maintaining normal midgut function and contributes to extended health and longevity in flies ([@B3]). Changes in mitochondrial biogenesis found in the midgut of *Indy* flies, combined with increased antioxidant activity and reduced production of reactive oxygen species preserve ISC homeostasis and intestinal integrity in *Indy* flies. These changes maintain midgut function and mediate extended health and longevity of *Indy* flies ([@B28]).

Reduced activity of the *Indy* homologs in other organisms is associated with similar metabolic effects that mimic CR. siRNA mediated knockdown of Indy/CeNac2, the worm *Indy* homolog, results in worms that are smaller, have reduced lipid levels, and have extended longevity ([@B8]; [@B32]). *mIndy^-/-^* knockout mice are protected from the negative effects of aging or a high-fat diet on metabolism, which include hepatic fat accumulation, obesity, and insulin insensitivity ([@B2]). These mice have increased energy expenditure, reduced hepatic lipogenesis, increased mitochondrial biogenesis, and enhanced hepatic fatty acid (FA) oxidation ([@B2]). Increased liver accumulation of diacylglycerols (DAG) and ceramides have been linked to insulin resistance and development of type 2-diabetes (T2D) ([@B17]). *mIndy^-/-^* mice have reduced DAG levels, which most likely contributes to their protection against insulin resistance. Whole-genome microarray studies comparing *mIndy^-/-^* and *mIndy^-/+^* revealed that transcriptional changes found in the liver of *mIndy^-/-^* mice are 80% identical to changes found in the liver of CR mice ([@B2]). All of these findings confer that INDY reduction creates a state similar to CR.

The metabolic effects of reduced INDY activity are a result of decreased cytoplasmic citrate levels. Citrate is converted to oxaloacetate and acetyl-CoA by ATP-citrate lyase. Acetyl-CoA is precursor for biosynthesis of triglycerides, FAs, low-density lipoproteins, and cholesterol. Citrate inhibits catabolism of glucose by inhibiting phosphofructokinase through allosteric modulation. Citrate also activates acetyl-CoA carboxylase, thereby affecting *de novo* lipogenesis. Thus, cytoplasmic citrate levels affect lipids and glucose metabolism, as well as energy production in mitochondria. Reduced *Indy* levels are associated with reduced ATP levels in *mIndy^-/-^* mice and in worms in which INDY levels are reduced by siIndy ([@B2]; [@B32]). The low ATP/ADP ratio activates AMPK, an energy sensor in the cells, which increases mitochondrial biogenesis by activating mitochondrial transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) ([@B10]; [@B23]; [@B2]; [@B28]; [@B32]). AMPK also increases insulin sensitivity, contributing to the beneficial effects of *Indy* reduction on glucose metabolism. When cytoplasmic citrate levels are high, FA β-oxidation is down regulated, while FA synthesis is upregulated. The opposite is found in *mIndy^-/-^* mice, in which low cytoplasmic citrate levels result in reduced FA synthesis, while FA β-oxidation and insulin sensitivity is increased ([@B2]).

Regulation of *mIndy* Transcription
===================================

The levels of fly INDY are affected by age and by caloric content of the food. Aging flies on a standard diet, young flies on a high calories diet, or young flies treated with paraquat (creating oxidative stress), have increased *Indy* mRNA and protein levels in the midgut ([@B28]). In contrast, flies aged on a CR diet have *Indy* mRNA reduced to 50% of the levels found in controls ([@B36]; [@B28]). Recent work showed that *mIndy* levels in primary rat hepatocytes are regulated by glucagon released during early starvation ([@B25]). Glucagon binds to the CREB (cAMP-dependent and cAMP-responsive element protein)-dependent binding site in the promoter region of *mIndy* and transiently increases *mIndy* expression (**Figure [2](#F2){ref-type="fig"}**) ([@B24]). *In vivo* studies shown increased hepatic *mIndy* levels in high-fat-diet-streptozotocin diabetic rats, in which CREB is constitutively active.

![**Transcriptional regulation of hepatic *mIndy* mRNA levels in model organisms and humans**. Hepatic *mIndy* expression levels are upregulated by glucagon released during early starvation via a cAMP and cAMP-responsive-element binding-protein (CREB)-dependent mechanism. A CREB binding site (C-BS) was identified in the promoter region of mINDY. Increased levels of interleukin-6 (IL-6) associated with inflammation and metabolic disease, activate transcription of hepatic *mIndy* via the signal transducer and activator of transcription 3 (STAT-3) signaling pathway. Diet and benzo\[a\]pyrene activate aryl hydrocarbon receptor (AhR) and its heterodimerization to AhR nuclear translocator (ARNT). In nucleus AhR activates transcription of *mIndy* via binding to potential binding site (BS) in the mIndy promoter ([@B25]). Rifampicin activates the pregnane X receptor (PXR), which increases *mIndy* transcription by activation of two enhancer modules located upstream of the *mIndy* (*SLC13A5*) transcriptional start site ([@B21]). Increased INDY levels result in higher citrate uptake and its incorporation in lipids, leading to non-alcoholic fatty liver disease (NAFLD), insulin resistance and type 2-diabetes (T2D).](fgene-08-00066-g002){#F2}

Additional findings link increased INDY to lipid metabolism. SLC13A5 has been identified as a novel transcriptional target of the pregnane X receptor (PXR) ([@B21]). The PXR has been linked to lipid metabolism and energy homeostasis. Rifampicin activates the PXR, which increases *mIndy* transcription by activation of two enhancer modules located upstream of the *mIndy* (*SLC13A5*) transcriptional start site ([@B21]). Rifampicin-induced PXR activation induces SLC13A5 mRNA and protein levels, and the lipid content in human primary hepatocytes, while SLC13A5 knockdown expression significantly reduces the lipid content in HepG2 cells ([@B21]). These data suggest a role of increased INDY levels in drug-induced steatosis in human liver.

Energy-rich diet and benzo\[a\]pyrene activate aryl hydrocarbon receptor (AhR). AhR heterodimerization to AhR nuclear translocator (ARNT) allows its translocation to nucleus and activation of *mIndy* transcription via binding to potential binding site in the mIndy promoter. AhR putative binding site has been identified in the promoter region of both rat and human mIndy ([@B25]). Activation of the AhR leads to fatty liver disease.

Patients undergoing Li^+^ treatment have dyslipidemia and gain body weight. The stimulatory effects of Li^+^ on the transporting activity of mINDY have been described, suggesting possible clinically relevant connection between increased INDY activity and obesity in humans ([@B16]). Taken together, increased hINDY levels may contribute to clinically relevant hepatic metabolic dysfunction associated with T2D.

Increased INDY Levels are Linked to Non-Alcoholic Fatty Liver Disease in Humans
===============================================================================

Two recent reports linked increased *mIndy* levels to non-alcoholic fatty liver disease (NAFLD) in an experimental mice model of NAFLD and human patients with NAFLD ([@B4]; [@B35]). NAFLD is associated with development of insulin resistance, T2D and liver cirrhosis ([@B6]; [@B27]). NAFLD results from sedentary life style, increased energy uptake, reduced FA oxidation, and possible altered gut microbiota ([@B27]). Diet-induced NAFLD in adult C57BL/6J mice fed a western diet was prevented by weekly injection of liver specific siRNA against mINDY, which suppressed 60% of liver *mIndy* levels after 8 weeks ([@B4]). These mice have improved hepatic insulin sensitivity, reduced hepatic lipid accumulation, and are protected against diet-induced lipid-steatosis. Notably, activation of the AhR leads to fatty liver disease and induces *mIndy* expression in rat hepatocytes, **Figure [2](#F2){ref-type="fig"}** ([@B25]).

The first direct link between increased hepatic mIndy levels and lipid steatosis in human NAFLD patients was reported by [@B35]. The authors showed that, in lean individuals, low levels of hepatic fat are associated with decreased mIndy expression, while in individuals with an increased body mass index and a high liver fat content mINDY levels are increased. Similarly, mINDY levels in the liver are increased in non-human primates aged on a high-fat or high-sucrose diet and in mice on a high-fat or a high fat-nonalcoholic steatohepatitis (NASH) inducing (low methionine, choline-deficient) diet. Liver microarray studies performed in samples from NAFLD patients and controls revealed an association between changes in whole-genome transcriptional levels in NAFLD liver samples and an increase in the expression of genes involved in lipid synthesis, metabolism, and immunological processes ([@B35]). An increase in interleukin-6 (IL-6) levels activates mIndy transcription via binding to the IL-6-receptor, which is associated with phosphorylation, activation of the transcription factor Stat3, and transfer of the latter to the nucleus, where it binds to the putative STAT-responsive element (STAT-RE) binding site in the *mIndy* promoter. The *in vivo* activation of the IL-6/Stat3 pathway increases mIndy expression and thereby citrate uptake and hepatic lipogenesis (**Figure [2](#F2){ref-type="fig"}**). In other *in vivo* studies, the administration of IL-6 for 14 days increased citrate uptake and FA synthesis in the livers of *mIndy^+/+^* mice, by increasing *mIndy* mRNA levels ([@B35]). This result confirmed the link between IL-6 and increased mIndy. The IL-6 mediated increase in mIndy citrate activity was confirmed by the lack of citrate uptake in hepatocytes isolated from *mIndy^-/-^* knockout mice, consistent with the link between mIndy and IL-6 ([@B35]).

*mIndy* is a Potential Therapeutic Target for Treating Hepatic Steatosis and Insulin Resistance
===============================================================================================

Considering the beneficial effects of the reduced transporting activity of INDY on metabolism and health, we and others have suggested mIndy (SLC13A5) as a target for the treatment of metabolic disorders (**Figure [1](#F1){ref-type="fig"}**; [@B31]; [@B2]; [@B9]; [@B38]; [@B29]). Several recent reports have described successful efforts to target the transporting activity of INDY and novel compounds have been identified that demonstrate the therapeutic potential of mINDY inhibitors in the treatment of NAFLD and insulin resistance. Temporal administrations of inducible hepatic 2′-*O*-methoxyethyl chimeric antisense oligonucleotides to knockdown *mIndy* levels in rats alleviated the negative effects of a high fat diet (HFD) and prevented diet-induced hepatic steatosis and hepatic insulin resistance without affecting rat body weight (**Figure [1](#F1){ref-type="fig"}**; [@B26]). These rats had lower serum triglyceride levels and improved hepatic insulin sensitivity. Several competitive stereo-specific inhibitors of mIndy transporting activity have been identified ([@B12], [@B13]). Small dicarboxylate molecules selectively inhibit mIndy citrate uptake *in vitro* in human hepatocytes and hepatic citrate uptake *in vivo* in mice. Compound 2 is a competitive inhibitor of mIndy that results in lower hepatic lipid levels, reduced plasma glucose levels, and a reversal of glucose intolerance in HFD-fed mice ([@B12]). Compound 4a is a potent mIndy inhibitor ([@B13]). Rodents treated with compound 4a had reduced citrate uptake in the liver, kidneys, and testis, which resulted in modest improvements in glucose metabolism ([@B13]).

Mutations in *mIndy* (*SLC13A5*) Lead to Autosomal-Recessive Epileptic Encephalopathy with Neonatal Seizures
============================================================================================================

Mutations in human *mIndy* cause autosomal-recessive epileptic encephalopathy with seizures during the first days of life and lead to developmental delays ([@B33]). *mIndy* encodes the only known neuronal plasma membrane Na-dependent citrate transporter, and gene mutations typically involve the sodium-binding domains of the respective protein. The key steps in mINDY-mediated citrate transport across the plasma membrane depend on conformational changes associated with Na-binding to critical residues within two mINDY domains. Thus, it has been speculated that the severe phenotype induced by human *mIndy* mutations is most likely due to the inability of mutated INDY to bind the sodium required for transporting citrate across the plasma membrane ([@B33]). *In vitro* studies showed that COS-7 cells transiently transfected with *mIndy* mutant genes lack citrate transport capacity ([@B18]). Recently, the European Consortium identified additional *mIndy* mutations that give rise to premature stop codons or amino acid substitutions in mINDY and result in the absence of citrate transport ([@B11]; [@B37]). These *mIndy* mutations are also associated with neonatal epilepsy, developmental delays, and variable cognitive impairment. Several patients have dental hypoplasia or hypodontia ([@B11]). Neuroimaging findings of eight full-term infants with *mIndy* mutations showed punctate white-matter lesions ([@B37]). Once in the cytoplasm, citrate is used for lipid, cholesterol, glucose, and glutamate synthesis. Malate derived from citrate is transported into mitochondria, where it is used for energy production. Thus, epilepsy may be due to disrupted energy production and altered metabolism in brain cells, an imbalance in GABA and glutamate production, or a reduced inhibition of excitatory *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors ([@B11]). However, the pathophysiology of *mIndy* mutations and the mechanism underlying severe phenotypes are unknown. Notably, *mIndy^-/-^* mice or mice treated with small mIndy competitive inhibitors did not develop seizures.

Summary and Concluding Thoughts
===============================

Reduction of *Indy* gene activity in flies and worms extends their health and longevity ([@B29]). Genetically reduced INDY expression has beneficial effects on metabolism and prevents diet-induced obesity in flies and mice, suggesting INDY as a target in the treatment of metabolic disorders in humans ([@B36]; [@B2]; [@B29]). This potential is supported by several findings. For example, reduced plasma insulin and plasma triglyceride levels as well as an improvement of hepatic steatosis were observed in HFD-fed mice and rats in which liver-specific knockdown of *Indy* was accomplished using a low-dose of a chimeric anti-sense oligonucleotide ([@B26]). Additional pharmacological treatments were recently described, such as competitive inhibitors of INDY transport activity that improve insulin sensitivity in rats and mice *in vivo* and in cultured human cells ([@B12], [@B13]).

By contrast, high levels of INDY are associated with negative effects on metabolism and health, while *mIndy* gene mutations cause autosomal-recessive epileptic encephalopathy in newborns as well as developmental delays ([@B33]; [@B35]). Further studies are needed to reveal the mechanisms that lead to this severe phenotype in patients. Recently, increased hepatic levels of *mINDY* were linked to insulin resistance and NAFLD in obese humans ([@B35]). These findings illustrate both the relevance of the *mIndy* gene to human health and a highly conserved role for INDY in the metabolism of a broad range of species. Thus, mIndy has emerged as a novel target for the treatment of age- and diet-associated metabolic syndrome, NAFLD, and T2D. The further development of mIndy inhibitors may additionally provide effective interventions targeting the debilitating health effects that are often associated with aging and will thereby allow a healthier life.
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